Inflammatory Acne Vulgaris
Conditions
Brief summary
The aim of this trial is to evaluate the safety and efficacy of the InMode RF Pro System with the Morpheus8 face tip (24 pins) applicator for the treatment of mild, moderate and severe, facial acne vulgaris
Detailed description
The aim of this trial is to evaluate the safety and efficacy of the InMode RF Pro System with the Morpheus8 face tip (24 pins) applicator for the treatment of mild, moderate and severe, facial acne vulgaris. Prospective, multicenter clinical study
Interventions
DEVICEMorpheus8 Applicator Radiofrequency device
Eligible subjects will receive 2 treatments with the Morpheus8 according to the study protocol. All participants will return for 2 follow up visits: 4 weeks (1M FU) and 12 weeks (3M FU) after the 2nd treatment. Total expected study duration is \ 6 months, depending on subject recruitment rate.
Sponsors
InMode MD Ltd.
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Intervention model description
Study Design Prospective, multicenter clinical study
Eligibility
Sex/Gender
ALL
Age
16 Years to No maximum
Healthy volunteers
Yes
Inclusion criteria
* Subject is \>16 years of age * General good health confirmed by medical history and examination of the treated area. * Subjects with mild to severe Acne Vulgaris, defined as a baseline IGA (Investigator's Global Assessment) score of 2, 3 or 4 and 10-100 inflammatory lesions (papules or pustules). * The patients should be willing to comply with the study procedure and schedule, including the follow up visits, and will refrain from using any other acne treatment methods during the entire study period. * Willing to avoid sun/UV exposure for duration of the study unless using sunscreen. * Willing to refrain from starting or changing hormonal contraception for duration of study. * Subject understands and is willing to sign the informed consent to participate in the study. Parental (or other) guardians must provide consent for minors under the age of 18.
Exclusion criteria
- Pacemaker or internal defibrillator, or any other active electrical implant anywhere in the body. * Patients who are under pharmacological anti-acne therapy (isotretinoin or antibiotics) for the last 6 months. * Use of botulinum toxin within prior 1 month. * Permanent implant in the treated area such as metal plates and screws, silicone implants or an injected chemical substance * Current or history of cancer, or premalignant condition in the treatment area. * Severe concurrent conditions, such as cardiac disorders, epilepsy, uncontrolled hypertension, and liver or kidney diseases. * Subject who are pregnant or nursing. * Started or changed hormonal contraceptive within prior month of study. * Subject is unwilling or unlikely to refrain from high UV exposure to face. * Impaired immune system due to immunosuppressive diseases such as AIDS and HIV, or use of immunosuppressive medications. * Patients with history of diseases stimulated by heat, such as recurrent Herpes Simplex in the treatment area * Poorly controlled endocrine disorders, such as diabetes or thyroid dysfunction. * Any active condition in the treatment area, such as sores, psoriasis, eczema, and rash. * History of skin disorders, keloids, abnormal wound healing, as well as very dry and fragile skin. * History of bleeding coagulopathies or use of anticoagulants in the last 10 days. * Any surgery in treated area within 3 months prior to treatment. * Subject received other treatments such as light, CO2 laser or RF in the treatment area within 6 months of study start date. * Simultaneous participation in another investigator drug or device study or completion of the follow-up phase for the primary endpoint of any previous study less than 30 days prior to the first evaluation in this study. * Subject that has any condition that, at the investigator's discretion, renders the subject unsuitable for participation in this clinical research study.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Percent of responder | Month 3 | Percent of responders, where responders are defined as subjects with at least a 50% reduction in number of inflammatory acne lesions from baseline to 12 weeks after the last treatment, as assessed by 3 independent reviewers using clinical photographs. Success Criteria: Success will be achieved if at least 50% of enrolled subjects are responders. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Percentage of subjects with a ≥2 point score improvement on the Investigators Global Assessment (IGA) scale | Month 3 | Percentage of subjects with a ≥2 point score improvement on the Investigators Global Assessment (IGA) scale at 12 weeks after the last treatment compared to baseline as assessed by three independent reviewers using clinical photographs. |
| Absolute change in non-inflammatory acne lesions | Month 3 | Absolute change In non-inflammatory acne lesions from baseline to 12 weeks after the last treatment, as assessed by 3 independent reviewers from clinical photographs |
| Absolute change in number of inflammatory acne lesions | Month 3 | Absolute change in number of inflammatory acne lesions from baseline to 12 weeks after the last treatment, as assessed by 3 independent reviewers using clinical photographs |
| percent change in non-inflammatory acne lesions | Month 3 | percent change in number of inflammatory acne lesions from baseline to 12 weeks after the last treatment, as assessed by 3 independent reviewers using clinical photographs |
| Percent change in non-inflammatory acne lesions | Month 3 | Percent change in non-inflammatory acne lesions from baseline to 12 weeks after the last treatment, as assessed by 3 independent reviewers from clinical photographs |
| The rate of patient satisfaction with treatment, | Month 3 | The rate of patient satisfaction with treatment, using a 5-point Likert scale at 12 weeks after the last treatment |
Countries
United States
Contacts
Primary ContactMeital Matalon, MS
Backup ContactMaria Shusterman, RN
Outcome results
None listed